iCo Therapeutics Inc. (ICO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 21, 2014
Pages: 34
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I2879A461F0EN
Leaflet:

Download PDF Leaflet

iCo Therapeutics Inc. (ICO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

iCo Therapeutics Inc. (iCo) is a pharmaceutical company. The company develops and commercializes drug candidates for treating ocular and systemic fungal diseases. Its products include iCo-007, iCo-008 and Oral AmpB Delivery System. iCo’s Oral AmpB Delivery System is a proprietary oral formulation of amphotericin B for treatment of systemic fungal infections in immunocompromised patients such as human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), cancer, transplant recipients, diabetics and some parasitic infections. The company’s iCo-008 is a human monoclonal antibody targeting eotaxin-1. Its iC0-007 is a new generation antisense candidate used for treatment of diabetic macular edema. iCo is headquartered in Vancouver, British Columbia, Canada.

iCo Therapeutics Inc. (ICO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
iCo Therapeutics Inc., Medical Devices Deals, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
iCo Therapeutics Acquires Rights For iCo-009 From The University of British Columbia
Partnerships
iCo Therapeutics Enters Into Co-Development Agreement With JDRF For iCo-007
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma
Licensing Agreements
iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab
Equity Offering
iCo Therapeutics Completes Public Offering Of Units For US$6.2 Million
iCo Therapeutics Completes Private Placement Of Shares Upon Exercise Of Warrants For US$1.4 Million
iCo Therapeutics Completes Public Offering Of Units For US$3.4 Million
iCo Therapeutics Completes Public Offering Of Units For US$2.5 Million
iCo Therapeutics Completes Non-Brokered Private Placement Of Units For US$1.1 Million
iCo Therapeutics Announces Private Placement Of US$10.4 Million
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants
iCo Therapeutics Completes Final Tranche Private Placement Of US$1.07 Million
iCo Therapeutics Completes Non-Brokered Private Placement Of US$0.41 Million
iCo Therapeutics Completes Private Placement Of US$1.15 Million
iCo Therapeutics Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
iCo Therapeutics Inc., Deals By Therapy Area, 2008 to YTD 2014
iCo Therapeutics Inc., Medical Devices Deals, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
iCo Therapeutics Acquires Rights For iCo-009 From The University of British Columbia
iCo Therapeutics Enters Into Co-Development Agreement With JDRF For iCo-007
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma
iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab
iCo Therapeutics Completes Public Offering Of Units For US$6.2 Million
iCo Therapeutics Completes Private Placement Of Shares Upon Exercise Of Warrants For US$1.4 Million
iCo Therapeutics Completes Public Offering Of Units For US$3.4 Million
iCo Therapeutics Completes Public Offering Of Units For US$2.5 Million
iCo Therapeutics Completes Non-Brokered Private Placement Of Units For US$1.1 Million
iCo Therapeutics Announces Private Placement Of US$10.4 Million
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants
iCo Therapeutics Completes Final Tranche Private Placement Of US$1.07 Million
iCo Therapeutics Completes Non-Brokered Private Placement Of US$0.41 Million
iCo Therapeutics Completes Private Placement Of US$1.15 Million
iCo Therapeutics Inc., Key Competitors
iCo Therapeutics Inc., Key Employees

LIST OF FIGURES

iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
iCo Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
iCo Therapeutics Inc., Medical Devices Deals, 2008 to YTD 2014
Skip to top


Ask Your Question

iCo Therapeutics Inc. (ICO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: